questionsmedicales.fr
Bactéries
Proteobacteria
Gammaproteobacteria
Vibrionaceae
Vibrio
Vibrio : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vibrio : Questions médicales les plus fréquentes",
"headline": "Vibrio : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vibrio : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vibrio"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vibrionaceae",
"url": "https://questionsmedicales.fr/mesh/D014737",
"about": {
"@type": "MedicalCondition",
"name": "Vibrionaceae",
"code": {
"@type": "MedicalCode",
"code": "D014737",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio alginolyticus",
"alternateName": "Vibrio alginolyticus",
"url": "https://questionsmedicales.fr/mesh/D044149",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio alginolyticus",
"code": {
"@type": "MedicalCode",
"code": "D044149",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.030"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae",
"alternateName": "Vibrio cholerae",
"url": "https://questionsmedicales.fr/mesh/D014734",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae",
"code": {
"@type": "MedicalCode",
"code": "D014734",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae non-O1",
"alternateName": "Vibrio cholerae non-O1",
"url": "https://questionsmedicales.fr/mesh/D044163",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae non-O1",
"code": {
"@type": "MedicalCode",
"code": "D044163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O1",
"alternateName": "Vibrio cholerae O1",
"url": "https://questionsmedicales.fr/mesh/D041241",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O1",
"code": {
"@type": "MedicalCode",
"code": "D041241",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.151"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O139",
"alternateName": "Vibrio cholerae O139",
"url": "https://questionsmedicales.fr/mesh/D041242",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O139",
"code": {
"@type": "MedicalCode",
"code": "D041242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Vibrio mimicus",
"alternateName": "Vibrio mimicus",
"url": "https://questionsmedicales.fr/mesh/D044164",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio mimicus",
"code": {
"@type": "MedicalCode",
"code": "D044164",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio parahaemolyticus",
"alternateName": "Vibrio parahaemolyticus",
"url": "https://questionsmedicales.fr/mesh/D014736",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio parahaemolyticus",
"code": {
"@type": "MedicalCode",
"code": "D014736",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.590"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio vulnificus",
"alternateName": "Vibrio vulnificus",
"url": "https://questionsmedicales.fr/mesh/D041261",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio vulnificus",
"code": {
"@type": "MedicalCode",
"code": "D041261",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vibrio",
"alternateName": "Vibrio",
"code": {
"@type": "MedicalCode",
"code": "D014733",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jaime Martinez-Urtaza",
"url": "https://questionsmedicales.fr/author/Jaime%20Martinez-Urtaza",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Jessica L Jones",
"url": "https://questionsmedicales.fr/author/Jessica%20L%20Jones",
"affiliation": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136."
}
},
{
"@type": "Person",
"name": "William C Walton",
"url": "https://questionsmedicales.fr/author/William%20C%20Walton",
"affiliation": {
"@type": "Organization",
"name": "2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA."
}
},
{
"@type": "Person",
"name": "Julia C van Kessel",
"url": "https://questionsmedicales.fr/author/Julia%20C%20van%20Kessel",
"affiliation": {
"@type": "Organization",
"name": "Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu."
}
},
{
"@type": "Person",
"name": "Blake Ushijima",
"url": "https://questionsmedicales.fr/author/Blake%20Ushijima",
"affiliation": {
"@type": "Organization",
"name": "Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Quantitative spectrofluorimetric method for determination of octreotide acetate synthetic peptide derivative in pure and its Sandostatin ampules forms.",
"datePublished": "2023-10-16",
"url": "https://questionsmedicales.fr/article/37864971",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.saa.2023.123546"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.",
"datePublished": "2022-08-29",
"url": "https://questionsmedicales.fr/article/36038805",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12328-022-01689-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fabrication of 3D-printed octreotide acetate-loaded oral solid dosage forms by means of semi-solid extrusion printing.",
"datePublished": "2022-12-30",
"url": "https://questionsmedicales.fr/article/36592893",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijpharm.2022.122569"
}
},
{
"@type": "ScholarlyArticle",
"name": "Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells.",
"datePublished": "2023-02-21",
"url": "https://questionsmedicales.fr/article/36804512",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MNM.0000000000001666"
}
},
{
"@type": "ScholarlyArticle",
"name": "Parahydrogen-induced polarization allows 2000-fold signal enhancement in biologically active derivatives of the peptide-based drug octreotide.",
"datePublished": "2023-04-19",
"url": "https://questionsmedicales.fr/article/37076553",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-33577-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Bactéries",
"item": "https://questionsmedicales.fr/mesh/D001419"
},
{
"@type": "ListItem",
"position": 3,
"name": "Proteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020560"
},
{
"@type": "ListItem",
"position": 4,
"name": "Gammaproteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020563"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vibrionaceae",
"item": "https://questionsmedicales.fr/mesh/D014737"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vibrio",
"item": "https://questionsmedicales.fr/mesh/D014733"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vibrio - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vibrio",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vibrio",
"description": "Comment diagnostiquer une infection à Vibrio ?\nQuels tests sont utilisés pour identifier Vibrio ?\nLes tests sérologiques sont-ils utiles ?\nPeut-on diagnostiquer Vibrio par PCR ?\nQuels symptômes orientent vers un diagnostic de Vibrio ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Octreotide&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vibrio",
"description": "Quels sont les symptômes d'une infection à Vibrio ?\nLa diarrhée est-elle toujours présente ?\nLes infections à Vibrio causent-elles de la fièvre ?\nY a-t-il des symptômes graves associés ?\nLes symptômes apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Octreotide&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vibrio",
"description": "Comment prévenir les infections à Vibrio ?\nLe lavage des mains est-il important ?\nLes vaccinations existent-elles contre Vibrio ?\nFaut-il éviter certains aliments ?\nLes voyages augmentent-ils le risque d'infection ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Octreotide&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vibrio",
"description": "Quel est le traitement principal pour Vibrio ?\nQuels antibiotiques sont efficaces contre Vibrio ?\nLa réhydratation est-elle toujours nécessaire ?\nLes traitements sont-ils différents selon le type de Vibrio ?\nLes probiotiques aident-ils dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Octreotide&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vibrio",
"description": "Quelles complications peuvent survenir avec Vibrio ?\nLa déshydratation est-elle une complication fréquente ?\nLes infections à Vibrio peuvent-elles être mortelles ?\nY a-t-il des risques pour les personnes immunodéprimées ?\nLes infections cutanées sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Octreotide&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vibrio",
"description": "Quels sont les principaux facteurs de risque pour Vibrio ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection ?\nLes personnes vivant près de l'eau sont-elles plus exposées ?\nLes voyages dans des zones endémiques sont-ils risqués ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Octreotide&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection à Vibrio ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des cultures bactériennes à partir d'échantillons de selles."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour identifier Vibrio ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de culture et des tests biochimiques spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les tests sérologiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sérologiques ne sont généralement pas utilisés pour Vibrio."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer Vibrio par PCR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut être utilisée pour détecter l'ADN de Vibrio dans les échantillons."
}
},
{
"@type": "Question",
"name": "Quels symptômes orientent vers un diagnostic de Vibrio ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes gastro-intestinaux comme la diarrhée aiguë peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection à Vibrio ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre."
}
},
{
"@type": "Question",
"name": "La diarrhée est-elle toujours présente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la diarrhée est fréquente mais pas systématique dans les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio causent-elles de la fièvre ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre peut accompagner les infections à Vibrio, mais ce n'est pas toujours le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes graves associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes graves peuvent inclure déshydratation et choc septique dans les cas sévères."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections à Vibrio ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de consommer des fruits de mer crus ou mal cuits et lavez-vous les mains."
}
},
{
"@type": "Question",
"name": "Le lavage des mains est-il important ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le lavage des mains réduit le risque d'infection par Vibrio et d'autres pathogènes."
}
},
{
"@type": "Question",
"name": "Les vaccinations existent-elles contre Vibrio ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin efficace contre les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains aliments ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, évitez les fruits de mer crus, surtout en période de chaleur ou d'épidémies."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque d'infection ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est endémique augmente le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour Vibrio ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la réhydratation, souvent accompagnée d'antibiotiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels antibiotiques sont efficaces contre Vibrio ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antibiotiques comme la doxycycline et l'azithromycine sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "La réhydratation est-elle toujours nécessaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réhydratation est cruciale, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents selon le type de Vibrio ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement peut varier selon le type de Vibrio et la gravité de l'infection."
}
},
{
"@type": "Question",
"name": "Les probiotiques aident-ils dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les probiotiques peuvent aider à restaurer la flore intestinale, mais ne remplacent pas le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Vibrio ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la déshydratation sévère, le choc septique et l'insuffisance rénale."
}
},
{
"@type": "Question",
"name": "La déshydratation est-elle une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la déshydratation est une complication courante, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio peuvent-elles être mortelles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans les cas graves, les infections à Vibrio peuvent être mortelles sans traitement rapide."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques pour les personnes immunodéprimées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées sont à risque accru de complications graves."
}
},
{
"@type": "Question",
"name": "Les infections cutanées sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Vibrio peut causer des infections cutanées, surtout après des blessures en milieu aquatique."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour Vibrio ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'immunodépression."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru de complications graves liées à Vibrio."
}
},
{
"@type": "Question",
"name": "Le diabète augmente-t-il le risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut augmenter le risque d'infections graves à Vibrio."
}
},
{
"@type": "Question",
"name": "Les personnes vivant près de l'eau sont-elles plus exposées ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être plus exposées aux infections à Vibrio, surtout en été."
}
},
{
"@type": "Question",
"name": "Les voyages dans des zones endémiques sont-ils risqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est courant augmente le risque d'infection."
}
}
]
}
]
}
A unique spectrofluorimetric protocol has been conceived for octreotide (a synthetic peptide drug) quantitation in both its authentic form and its application to dosage form. The protocol has been est...
The presence of neuroendocrine liver metastases is one of the poorest prognostic factors in patients with pancreatic neuroendocrine neoplasms, and surgical resection of neuroendocrine liver metastases...
Semi-solid extrusion (SSE) 3D printing technology was utilized for the encapsulation of octreotide acetate (OCT) into 3D-printed oral dosage forms in ambient conditions. The inks and the OCT-loaded 3D...
Differentiated neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs), targets for therapy with either unlabeled or radioactively labeled somatostatin analogs (SSA). Associated with worse...
The NET cell lines BON-1 and QGP-1 were incubated with the Wnt-inhibitors 5-aza-2'-deoxycytidine (5-aza-CdR), Quercetin, or Niclosamide, or the Wnt activator lithium chloride (LiCl). Expression of SST...
The mRNAs of SSTRs 1-5 were expressed in both cell lines. Wnt inhibitors caused downregulation of Wnt target genes, while 5-aza-CdR had the highest inhibitory effect. LiCl lead to an upregulation of W...
We demonstrate here that Wnt signaling orchestrates SSTR expression and function in a preclinical NET model. Wnt inhibition increases [125I-Tyr3]octreotide uptake offering an opportunity to enhance th...
Octreotide, a somatostatin analogue, has shown its efficacy for the diagnostics and treatment of various types of cancer, i.e., in octreotide scan, as radio-marker after labelling with a radiopharmace...
CHI is a relevant cause of persistent and severe hypoglycemia and the ABCC8 gene mutation is one of most common cause of the disease. Two main types of CHI have been described, diffuse and focal form....
We present a case of an infant with a diazoxide-unresponsive focal form of CHI, due to ABCC8 mutation ABCC8, treated with octreotide. To better evaluate the glycemic trend, a CGM was placed. In order ...
The adoption of the CGM and insulin pump, allowed a better personalization of the therapy and a reduction of acute carbohydrate intake, promoting a good auxological growth before resolutive surgery. W...
In many cases, pleurodesis is the only treatment available for the treatment of malignant pleural effusion (MPE), and in the case of excessive daily pleural effusion, its therapeutic effect may be red...
This study was a single-center, placebo-controlled, and triple-blind, randomized trial designed to investigate the therapeutic effects and safety of octreotide in patients with MPE in Tehran, Iran, fr...
A total of 46 patients (23 in the octreotide group and 23 in the placebo group) with MPE was included in this study. Our findings demonstrated that adjunctive treatment with subcutaneous octreotide in...
Our findings demonstrated that adjunctive treatment with subcutaneous octreotide increases the efficacy of pleurodesis with talc powder without any significant side effects. Future studies with a larg...
Iranian Registry of Clinical Trials, IRCT20210915052492N1. Registered 11 October 2021 - Retrospectively registered, https://www.irct.ir/trial/58776 ....
Somatostatin receptor scintigraphy with 99m Tc-Tektrotyd is widely used for the investigation of neuroendocrine tumors. Overexpression of somatostatin receptors has been shown in different tumor types...
Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs). Lanreotide is m...
Randomized, single-blinded study. Patients with NETs received injections every 4 weeks. Arm 1: octLAR × 3, then lanreotide × 3; arm 2: reverse order. Self-reported injection site pain scores (range, 0...
Fifty-one patients enrolled (26 in arm 1 and 25 arm 2), all evaluable for primary end point. No significant difference was identified in the mean pain score over the first three injections (2.4 ± 1.9...
We found minimal pain with octLAR and lanreotide and no significant pain score differences between the two. Patients indicating a drug preference trended toward favoring octLAR....
GEP-NETs are heterogeneous tumors originating from the pancreas (panNET) or the intestinal tract. Only a few patients with NETs are amenable to curative tumor resection, and for most patients, only pa...